Jorg Eder

Basel, BS 4002, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β.

Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β.

Journal: Nature communications

Published: December 12, 2022

Low-molecular weight inhibitors of the alternative complement pathway.

Low-molecular weight inhibitors of the alternative complement pathway.

Journal: Immunological reviews

Published: October 11, 2022

Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition.

Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition.

Journal: Journal of molecular biology

Published: August 13, 2021

Pharmacological inhibition of IKKβ dampens NLRP3 inflammasome activation after priming in the human myeloid cell line THP-1.

Pharmacological inhibition of IKKβ dampens NLRP3 inflammasome activation after priming in the human myeloid cell line THP-1.

Journal: Biochemical and biophysical research communications

Published: January 15, 2021

Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer.

Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer.

Journal: Cancer immunology research

Published: November 05, 2020

Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.

Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.

Journal: Journal of medicinal chemistry

Published: February 20, 2020

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 31, 2019

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans.

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans.

Journal: Blood

Published: October 23, 2018

An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.

An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.

Journal: Nature chemical biology

Published: December 12, 2017

Opportunities and challenges in phenotypic drug discovery: an industry perspective.

Opportunities and challenges in phenotypic drug discovery: an industry perspective.

Journal: Nature reviews. Drug discovery

Published: July 08, 2017

Small-molecule factor D inhibitors targeting the alternative complement pathway.

Small-molecule factor D inhibitors targeting the alternative complement pathway.

Journal: Nature chemical biology

Published: May 20, 2016

Targeted inhibition of the COP9 signalosome for treatment of cancer.

Targeted inhibition of the COP9 signalosome for treatment of cancer.

Journal: Nature communications

Published: January 22, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026